ReviewHistology and histopathology2023
Prognostic factors of breast phyllodes tumors.
Review in Histology and histopathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 8 citations in OpenAlex.
- Optimal surgical margin and the efficacy of adjuvant radiotherapy in borderline and malignant phyllodes tumors: a multicenter retrospective study.Radiation oncology journal · 2026Article
- Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors.Life (Basel, Switzerland) · 2025Review
- Malignant phyllodes tumor of the breast with short-term multiple recurrences and systemic distant metastasis: a case report and literature review.Frontiers in oncology · 2025Article
- Expression patterns of H3K27me3 for differentiation of breast fibroadenomas and phyllodes tumors.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2025Article
- Clinicopathological features and risk factors for local recurrence of breast phyllodes tumors: a dual-center, 12-year, retrospective study.Frontiers in oncology · 2025Article
- Article
- Fibroepithelial lesions: assessing the risk of malignant phyllodes tumors in the breast.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
- Clinical Predictors and Long-term Outcomes of Non-benign Breast Phyllodes Tumors.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhyllodes tumor (PT) is a relatively rare breast tumor, accounting for <1% of all breast tumors. MAIN BODY: Adjuvant therapy with chemotherapy or radiation therapy, other than surgical excision, has not been established yet. PT, similar to other breast tumors, is classified as benign, borderline, and malignant according to the World Health Organization classification system, depending on stromal cellularity, stromal atypia, mitotic activity, stromal overgrowth, and tumor border. However, this histological grading system cannot effectively or fully reflect the clinical prognosis of PT. Several studies have investigated prognostic factors for PT as some PTs recur or metastasize to distant sites, and thus, prediction of prognosis is clinically imperative.
conclusionThis review discusses clinicopathological factors, immunohistochemical markers, and molecular factors that have been investigated in previous studies to have an impact on the clinical prognosis of PT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.